ExpressCells Appoints Wendy DiCicco to Board of Directors
Brings financial and operational expertise to company leadership
By: ExpressCells, Inc.
"We are thrilled to have Wendy join ExpressCells' Board of Directors," said Matt Handel, Chief Executive Officer. "She has deep business and finance knowledge that will strengthen ExpressCells' capital-raising and decision-making capabilities. I look forward to working with her as we grow ExpressCells and commercialize our custom and catalog cell lines."
"I am honored to join ExpressCells and help the company expand its commercialization and capital raise activities. ExpressCells brings a unique, much-needed solution to drug discovery companies resulting in higher quality cell lines with as much as 75% efficiency in the knock-in process," said Ms. DiCicco. "I look forward to making ExpressCells a vibrant research tools company."
In addition to ExpressCells, Ms. DiCicco serves on the boards of EyePoint Pharmaceuticals —chairing the Audit Committee—and Carmell Therapeutics. She previously served on three additional boards in the life sciences and semiconductor industries, chairing audit, compensation and governance committees. Ms. DiCicco is an advisory consultant for emerging growth companies, often serving as interim CFO. Most recently, she was COO and CFO of Centinel Spine and was previously President and COO at Camber Spine Technologies. Prior to these two privately-held spinal technology companies, she was CFO for several private and public medical device and biotechnology companies, including 12 years at Kensey Nash Corporation. Ms. DiCicco started her career with Deloitte & Touche in audit assurance. Ms. DiCicco also serves in the community on non-profit boards, including the Philadelphia Chapter of the National Association of Corporate Directors (NACD), where she is a Board Leadership Fellow. Ms. DiCicco graduated from Philadelphia College of Textiles and Science with a B.S. degree in Accounting and is a CPA in the state of Pennsylvania.
ExpressCells is a private biotechnology company based in Philadelphia, PA. Its propriety genome editing technology, in combination with CRISPR/Cas9, creates advanced, knock-in cell line up to 75% faster than older processes. This technology allows ExpressCells to insert up to three genes into the same cell line.
ExpressCells' first knock-in cell lines code for bioluminescent and fluorescent proteins. These allow scientists to more see the results of their experiments in real time. ExpressCells sells both custom cell lines—each designed to meet the specific requirements of an individual scientist—and catalog cell lines. For more information, visit www.xpresscells.com.
+1 (484) 483-6759